Hershey Medical Center Research Trials: February 2025 (Liver Center)

Research StudiesSeladelparPBC
Written By Wilson Jackson

AMPED

The purpose of this trial is to test different levels of exercise needed to reduce liver fat in patients with NASH.

Key inclusion:

  • Diagnosed with a severe form of nonalcoholic fatty liver disease known as nonalcoholic steatohepatitis and have a liver biopsy proving NASH within six months of enrollment

  • Be age 18 to 69

Study contact:

AFFIRM

A Randomized, Double-Blind, Placebo-Controlled Study to

PBC with Cirrhosis

Study contact:

EL-FIT NASH

This study will be a pilot study to evaluate the workability, safety and acceptability of Exercise and Liver FITness (EL-FIT), a mHealth exercise training program previously confirmed in patients with cirrhosis,(1) in patients with Nonalcoholic Steatohepatitis (NASH)

Key inclusion:

  • Be ages 18 years or older

  • Have been diagnosed with nonalcoholic fatty liver disease (NAFLD)

  • Have a smart phone and fitness watch

Study contact:

ESSENCE

Nonalcoholic Steatohepatitis (NASH) is associated with increased risk of mortality. Currently, there are few treatment options. Therefore, there is a need for an effective and safe medication treatment options. Semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1 RA), can address certain aspects of NASH and is therefore considered a strong candidate for the treatment of NASH.

Key inclusion:

  • Be diagnosed with nonalcoholic steatohepatitis

  • Be ages 18 and older

Study contact:

KOWA NASH

This phase 2 trial will assess efficacy and safety of K-001 once daily K-877-ER 0.4 mg QD, and CSG452 20 mg QD in subjects with noncirrhotic NASH with liver fibrosis.

Key inclusion:

  • Be diagnosed with nonalcoholic steatohepatitis

  • Be ages 18 and older

Study contact:

A Phase 2b, Prospective, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate Efficacy and Safety of Saroglitazar Magnesium in Subjects with Nonalcoholic Steatohepatitis and Fibrosis

Key inclusion:

  • Diagnosed with a severe form of nonalcoholic fatty liver disease known as nonalcoholic steatohepatitis

  • Ages 18 and older

Study contact:

More nonalcoholic steatohepatitis (NASH) research studies

Additional studies are under review and will be accepting participants soon. Adults 18 and older with a diagnosis of nonalcoholic steatohepatitis (NASH) may be eligible.

Contact the study team to learn more:

Study contact:

A Randomized, Double Blind, Placebo Controlled, Phase 2 Study of SiRNA Gene Silencing for the Treatment of Nonalcoholic Steatohepatitis (NASH) in Participants with Genetic Risk Factors

Key inclusion:

  • Adult male or female ≥18 years and ≤75 years of age.

  • Diagnosed with NASH F2 or F3

  • Genotype criteria (tested during screening)

Study contact:

Wilson Jackson
Next

Hershey Medical Center Research Trials: February 2025 (Crohn’s, Celiac, and Ulcerative Colitis)